Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 3/20 | 0.35 |
| ▸ | CTSS | P25774 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | PSD | A5PKW4 | 2/20 | 0.33 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.33 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | PDE8A | O60658 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19771672 | 0.98 | HRH4 (0.41) | HRH4L3MBTL1CTSKCTSSHRH3 | |
| SCHEMBL3214532 | 0.98 | HRH4 (0.41) | HRH4L3MBTL1CTSKCTSSHRH3 | |
| SCHEMBL20798062 | 0.96 | HRH4 (0.38) | HRH4L3MBTL1CTSKCTSSHRH3 | |
| SCHEMBL3852030 | 0.91 | CYP17A1 (0.34) | HRH4L3MBTL1 | |
| SCHEMBL16220098 | 0.82 | KDM5B (0.40) | PDE8A | |
| SCHEMBL16220100 | 0.81 | CNR2 (0.32) | — | |
| SCHEMBL1615966 | 0.80 | HRH4 (0.61) | HRH4HRH3 | |
| SCHEMBL8321238 | 0.79 | HRH4 (0.59) | HRH4HRH3 | |
| SCHEMBL16212020 | 0.76 | NPC1 (0.33) | — | |
| SCHEMBL3718738 | 0.76 | HRH4 (0.56) | HRH4HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655688-B | Substituted pyrrolopyridines as ATR inhibitors | 蓝谷制药有限责任公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2022-07-21 | — | — | US | disclosed |
| EP-3679041-B1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | NEWAVE PHARMACEUTICAL INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2022-02-01 | — | — | US | disclosed |
| CN-111655688-A | Substituted pyrrolopyridines as ATR inhibitors | 蓝谷制药有限责任公司 | 2020-09-11 | — | — | CN | disclosed |
| EP-3679041-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200207763-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | GREENGENE BIOSCIENCES INC. | 2020-07-02 | — | — | US | disclosed |
| WO-2019050889-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | BLUEVALLEY PHARMACEUTICAL LLC (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-06-10 | — | — | US | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
| WO-2010028179-A1 | HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144722-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS GATA MODULATORS | GATAD2B, GATAD2A, RUNX1 | HRH4 1793/4885L3MBTL1 3769/4885CTSK 2142/4885 |
| US-20220227755-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | HRH4 3528/4885L3MBTL1 653/4885CTSK 4219/4885 |
| US-11236089-B2 | Substituted pyrrolopyridines as ATR inhibitors | ATR, RB1, ATRIP | HRH4 3528/4885L3MBTL1 653/4885CTSK 4219/4885 |
| US-20200207763-A1 | SUBSTITUTED PYRROLOPYRIDINES AS ATR INHIBITORS | ATR, RB1, ATRIP | HRH4 3528/4885L3MBTL1 653/4885CTSK 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.